Press ReleaseView printer-friendly version << Back
vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
Prior to the Cantex agreement, vTv was developing azeliragon for the treatment of Alzheimer’s disease. Through these efforts, vTv generated a significant body of clinical data supporting the safety and tolerability profile of azeliragon. Evidence suggests that RAGE—ligand interactions play a vital role in cancer, as well as in a range of inflammatory diseases.
“We would like to congratulate Cantex on receipt of this important addition to the azeliragon patent estate covering its use as a potential therapy for GBM. Coupled with the Orphan Drug Designation granted for this indication in early 2023, Cantex is building robust protections around this novel small molecule RAGE inhibitor, aimed at maximizing the commercial opportunities for azeliragon should its clinical development be successful,” said
Azeliragon is an orally administered small molecule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the glioblastoma microenvironment. By preventing interaction of RAGE with these ligands, azeliragon may inhibit glioblastoma and overcome its resistance to effective treatment. Azeliragon was originally under development for Alzheimer's disease by
This release contains forward-looking statements, which involve risks and uncertainties, including statements regarding the potential grant of the FDA Approval. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the agreements and transactions described in this release are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors, including the risk that the FDA Approval is not received on a timely basis or at all, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the
Source: vTv Therapeutics Inc.